DaVita (DVA) is trading down at $180.70 (-0.76%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on DVA
One firm's current price target on DaVita: $220 — 22% above the current $181. Each is tracked to its date and scored the same way a member's call is.
- TD Cowen $184 → $220 by Aug 2027 Aug 7, 2026 via Yahoo Finance · TD Cowen's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
DaVita revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $10.7B | $10.9B | $11.4B | $11.4B | $11.6B | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Growth (year over year) | — | +1.6% | +4.9% | −0.1% | +1.4% | +0.6% | −0.1% | +4.6% | +5.6% | +6.5% |
| Operating income | $2.03B | $1.81B | $1.53B | $1.64B | $1.69B | $1.80B | $1.34B | $1.60B | $2.09B | $2.04B |
| Operating margin | 19.0% | 16.7% | 13.4% | 14.4% | 14.7% | 15.5% | 11.5% | 13.2% | 16.3% | 15.0% |
| Net income | $879.9M | $663.6M | $159.4M | $811.0M | $773.6M | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| Net margin | 8.2% | 6.1% | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
| EPS (diluted) | $4.29 | $3.47 | $0.92 | $5.27 | $6.31 | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 |
| Balance sheet | ||||||||||
| Cash and equivalents | $674.8M | $508.2M | $323.0M | $1.10B | $325.0M | $461.9M | $244.1M | $380.1M | $794.9M | $676.4M |
| Total assets | $18.8B | $19.0B | $19.1B | $17.3B | $17.0B | $17.1B | $16.9B | $16.9B | $17.3B | $17.5B |
| Total liabilities | $12.9B | $13.1B | $14.1B | $13.8B | $14.1B | $14.8B | $14.7B | $14.2B | $15.2B | $16.3B |
| Long-term debt | $8.94B | $9.16B | $8.17B | $7.98B | $7.92B | $8.73B | $8.69B | $8.27B | $9.18B | $10.2B |
| Shareholders' equity | $4.65B | $4.69B | $3.70B | $2.13B | $1.38B | $755.5M | $712.3M | $1.06B | $121.1M | −$651.1M |
| Cash flow | ||||||||||
| Operating cash flow | $1.97B | $1.91B | $1.77B | $2.07B | $1.98B | $1.93B | $1.56B | $2.06B | $2.02B | $1.89B |
| Capital expenditure | $829.1M | $905.3M | $987.1M | $766.5M | $674.5M | $641.5M | $603.4M | $568.0M | $555.4M | $575.9M |
| Free cash flow | $1.14B | $1.01B | $784.5M | $1.31B | $1.30B | $1.29B | $961.1M | $1.49B | $1.47B | $1.31B |
| Dividends paid | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Share buybacks | $1.10B | $802.9M | $1.16B | $2.38B | $1.46B | $1.54B | $802.2M | $272.2M | $1.39B | $1.31B |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.26B | $3.29B | $3.22B | $3.38B | $3.42B | $3.62B | $3.42B | $3.55B |
| Growth (year over year) | +4.6% | +4.7% | +5.0% | +6.1% | +4.8% | +9.9% | +6.0% | +5.2% |
| Operating income | $534.9M | $565.4M | $438.9M | $537.8M | $505.8M | $561.1M | $481.9M | $579.0M |
| Operating margin | 16.4% | 17.2% | 13.6% | 15.9% | 14.8% | 15.5% | 14.1% | 16.3% |
| Net income | $214.7M | $259.3M | $162.9M | $199.3M | $150.3M | $234.2M | $197.5M | $265.4M |
| Net margin | 6.6% | 7.9% | 5.1% | 5.9% | 4.4% | 6.5% | 5.8% | 7.5% |
| EPS (diluted) | $2.50 | $3.08 | $2.00 | $2.58 | $2.04 | $3.22 | $2.87 | $4.02 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.07B | $794.9M | $438.8M | $708.4M | $706.0M | $676.4M | $644.2M | $669.0M |
| Total assets | $17.5B | $17.3B | $17.1B | $17.5B | $17.6B | $17.5B | $17.5B | $17.7B |
| Total liabilities | $15.3B | $15.2B | $15.5B | $15.9B | $16.2B | $16.3B | $16.5B | $16.6B |
| Long-term debt | $9.26B | $9.18B | $9.56B | $10.1B | $10.2B | $10.2B | $10.5B | $10.7B |
| Shareholders' equity | $386.7M | $121.1M | −$267.1M | −$369.6M | −$571.9M | −$651.1M | −$755.5M | −$765.1M |
| Cash flow | ||||||||
| Operating cash flow | $810.4M | $547.6M | $180.0M | $324.2M | $841.5M | $540.7M | $320.8M | $490.1M |
| Capital expenditure | $139.0M | $170.7M | $143.3M | $121.1M | $166.1M | $145.4M | $102.0M | $169.8M |
| Free cash flow | $671.4M | $377.0M | $36.8M | $203.1M | $675.4M | $395.3M | $218.8M | $320.3M |
| Share buybacks | $407.9M | $365.4M | $510.2M | $283.7M | $240.1M | $274.5M | $196.4M | $181.5M |
From DaVita's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About DaVita
DaVita Inc. is an American health care company, incorporated in Delaware and headquartered in Denver, that provides kidney dialysis services through a network of 2,657 outpatient centers in the United States. DaVita serves 200,500 patients, and has 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
- Headquarters
- Denver, Colorado From SEC filings, Oct 2026
Recent News (11)
-
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) Seeking Alpha
-
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and …
-
DaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidance
DaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidance
-
Are Wall Street Analysts Bullish on DaVita Stock?
Are Wall Street Analysts Bullish on DaVita Stock?
-
DaVita Shares Rise After TD Cowen Upgrades Stock to Buy DaVita Shares Rise After TD Cowen Upgrades Stock to Buy
-
DaVita Inc. Q2 2026 Earnings Call Summary DaVita Inc. Q2 2026 Earnings Call Summary
-
Earnings call transcript: DaVita beats Q2 2026 estimates but shares fall
Earnings call transcript: DaVita beats Q2 2026 estimates but shares fall
-
DaVita Inc. 2nd Quarter 2026 Results DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had …
-
Moon Capital Management Exited DaVita (DVA) with 174% total Return Moon Capital Management Exited DaVita (DVA) with 174% total Return
-
-
More Health Care stocks
- CRL Charles River Laboratories
- CVS CVS Health
- DGX Quest Diagnostics
- DHR Danaher Corporation
- DXCM Dexcom
- ELV Elevance Health
- EW Edwards Lifesciences
- GEHC GE HealthCare